Chemotherapy of Hodgkin's disease.
Chemotherapy is the main treatment for advanced Hodgkin's disease as demonstrated by the NCI MOPP study. The main prognostic factors have been identified. ABVD is partially non cross-resistant and permits the alteration of two regimens in order to achieve greater efficacy. The respective impact of conventional and high-dose chemotherapy for salvage treatment is being evaluated. Long-term hazards due to different regimens require continuous assessment so that the choice and modalities of chemotherapy in localized disease may be determined.
Carde
P
P
Institut Gustave-Roussy, Villejuif, France.
D000971:Antineoplastic Combined Chemotherapy Protocols / Q000009:adverse effects / Q000627:therapeutic use*; D001761:Bleomycin / Q000008:administration & dosage; D016026:Bone Marrow Transplantation; D003606:Dacarbazine / Q000008:administration & dosage; D004317:Doxorubicin / Q000008:administration & dosage; D004334:Drug Administration Schedule; D006689:Hodgkin Disease / Q000188:drug therapy*; D006801:Humans; D008466:Mechlorethamine / Q000008:administration & dosage; D011241:Prednisone / Q000008:administration & dosage; D011344:Procarbazine / Q000008:administration & dosage; D014747:Vinblastine; D014750:Vincristine / Q000008:administration & dosage
D001761:Bleomycin; D011344:Procarbazine; D008466:Mechlorethamine; D014750:Vincristine; D014747:Vinblastine; D003606:Dacarbazine; D004317:Doxorubicin; D011241:Prednisone